New oral cancer drug enters first human safety trial

NCT ID NCT06484985

Recruiting now Disease control Sponsor: Axter Therapeutics (Beijing) Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tests a new oral drug, AXT-1003, in 78 people with advanced non-Hodgkin lymphoma or solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. Researchers will also look for signs that the drug shrinks tumors, but this is not yet a test of effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AXT-1003 (an oral capsule)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced cancers that have not responded to standard therapies.
What could go wrong: This is a very early Phase 1 trial focused on safety, not effectiveness. It is small (78 people) and may not lead to a working treatment. Side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mature T-cell and NK-cell non-Hodgkin lymphoma neoplasm non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

Beijing Cancer Hospital
RECRUITING

Beijing, China
Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, China
Fujian Cancer Hospital
RECRUITING

Fuzhou, China
Hunan Cancer Hosptial
RECRUITING

Changsha, China
Sun Yat-Sen University Cancer Center
RECRUITING

Guangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.